Chiadi Onyike, Associate Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
Dr. Chiadi Onyike directs clinical and research programs at Johns Hopkins University that are focused on neurodegenerative disorders in young and middle-age adults. The research programs focus on the epidemiology, neuropsychiatry and clinical management of frontotemporal dementias, young-onset Alzheimer disease, spinocerebellar ataxias, Lewy body disease, prion diseases, and other neurodegenerative diseases. He is a principal investigator and co-investigator of NIH, foundation, industry and philanthropy sponsored research projects. He is Chair-elect of the Medical Advisory Council of the Association for Frontotemporal Degeneration, and also serves on the Alzheimer's Association Best Clinical Practices Guidelines Work Group, the FTD Disorders Registry Scientific Advisory Board, the FDA Advisory Committee for Central and Peripheral Nervous System Drugs, and the Executive Committee of the International Society for Frontotemporal Dementias. Dr. Onyike received his Medical Degree from the University of Nigeria, and a graduate degree in Clinical Epidemiology from the Johns Hopkins Bloomberg School of Public Health. His training includes internships at the University of Nigeria Teaching Hospital and St. Elizabeth's/CMHS in Washington D.C., residency in Adult Psychiatry and fellowship in General Hospital Psychiatry (Johns Hopkins School of Medicine), and research fellowships in Neurochemistry/Cell Signaling (University of Maryland at Baltimore) and Psychiatric Epidemiology (Johns Hopkins Bloomberg School of Public Health).
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Alector, Inc.Topic:Clinical trial for hereditary frontotemporal dementiaDate added:Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:DenaliTopic:Clinical trial for hereditary frontotemporal dementiaDate added:04/03/2023Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:OtsukaTopic:FDA Mock consultation for treatment of agitation in dementiaDate added:04/03/2023Date updated:04/29/2024Relationship end date:02/06/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ReataTopic:FDA Mock consultation for Friedrich's ataxia treatmentDate added:04/03/2023Date updated:04/29/2024Relationship end date:06/22/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AcadiaTopic:FDA Mock consultation for treatment of psychosis in Alzheimer diseaseDate added:04/03/2023Date updated:04/29/2024Relationship end date:04/22/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Eli LillyTopic:FDA Mock consultation for Alzheimer disease treatmentDate added:04/29/2024Date updated:04/29/2024Relationship end date:05/31/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ZevraTopic:FDA Mock consultation for Niemann-Pick C treatmentDate added:04/29/2024Date updated:04/29/2024Relationship end date:02/26/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Transposon, Inc.Topic:Clinical trial for hereditary Frontotemporal dementiaDate added:04/29/2024Date updated:04/29/2024Relationship end date:10/31/2023
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.